虽然肝癌患者受益于栓塞治疗不仅表现在不可切除的患者，而且它正在作为桥梁治疗用于等待肝移植的病人，其依据的假设是，这一方法可能会阻止肿瘤进展导致的病情恶化[13] 。
肝动脉栓塞治疗肝癌的角色扮演中主要起辅助治疗的作用。在治愈性治疗的作用方面还没有来得及证实已经被以影像引导下射频消融为代表的局部温度介入治疗无情地取代，还包括微波和冷冻治疗。在配合其它治疗所进行的新辅助治疗方面正在积极的探索之中，典型的是以局部射频消融联合TACE。 1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J. Clin.55(2),74–108 (2005). 2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med.340(10),745–750 (1999). 3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362(9399),1907–1917 (2003). 4. Doyon D, Mouzon A, Jourde AM et al. [Hepatic, arterial embolization in patients with malignant liver tumours (author’s transl)]. Ann. Radiol. (Paris)17(6),593–603 (1974). 5. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359(9319),1734–1739 (2002).（European randomized controlled trial (RCT) showing that chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC) when compared with conservative treatment）. 6. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology35(5),1164–1171 (2002).（Asian RCT showing that transarterial lipiodol chemoembolization compared with supportive care significantly improves survival in patients with unresectable HCC.） 7. Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology224(1),47–54 (2002).（Meta-analysis: embolization reduces mortality in patients with unresectable HCC. No significant differences between transarterial chemoembolization (TACE) and transarterial embolization (TAE) were found. Analysis limited by differences in the baseline severity of illness in the population, differences in the chemoembolization procedures and lack of data regarding confounding factors）. 8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology37(2),429–442 (2003).（Meta-analysis: TACE with cisplatin or doxorubicin demonstrated better survival than control group (conservative management or suboptimal therapies). Embolization alone did not show a survival benefit ）. |